About The Study: This proof-of-concept randomized clinical trial provides insights into the therapeutic potential of interleukin 6 (IL-6) or IL-6 receptor inhibition for depression and highlights suitable patient selection methods. Interleukin 6, a keystone inflammatory cytokine, is a credible mechanistic candidate for causing depression.
Corresponding Authors: To contact the corresponding authors, email Éimear M. Foley, PhD ( eimear.foley@bristol.ac.uk ) and Golam M. Khandaker, PhD, ( golam.khandaker@bristol.ac.uk ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(10.1001/jamapsychiatry.2026.1053)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1053?guestAccessKey=b62cde62-853f-4f80-a300-55745bef474a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026
JAMA Psychiatry